Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials

Bipolar Disorders

Volumn 10, Issue 2, 2008, Pages 323-333

  Calabrese, Joseph R ^a   Huffman, Russell F ^b   White, Robin L ^b   Edwards, Suzanne ^b   Thompson, Thomas R ^b   Ascher, John A ^b   Monaghan, Eileen T ^b   Leadbetter, Robert A ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Bipolar depression; Bipolar disorder; Depression; Lamotrigine

Indexed keywords

LAMOTRIGINE; PLACEBO;

ABNORMAL DREAMING; ADULT; AMBLYOPIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DYSPEPSIA; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INFECTION; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TRIAZINES;

EID: 43149119463     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2007.00500.x     Document Type: Article

References (34)

1. Anonymous. Bipolar depression and rapid cycling: The latest pharmacologic strategies. Brown Univ Child Adolesc Psychopharmacol 2002; 13: 10-12.
2. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
3. Sachs GS, Koslow CL, Ghaemi SN. The treatment of bipolar depression. Bipolar Disord 2000; 2: 256-260.
4. Malhi GS, Mitchell PB, Salim S. Bipolar depression: Management options. CNS Drugs 2003; 17: 19-25.
5. MacQueen GM, Young LT, Robb JC et al. Effect of number of episodes on well-being and functioning of patients with bipolar disorder. Acta Psychiatr Scand 2000; 101: 374-381.
6. Robb JC, Cooke RG, Devins GM et al. Quality of life and lifestyle disruption in euthymic bipolar disorder. J Psychiatr Res 1997; 31: 509-517.
7. Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50: 201-213.
8. Kupfer DJ, Frank E, Grochocinski VJ et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63: 120-125.
9. Isommetsa ET, Henriksson MM, Aro HM et al. Suicide in bipolar disorder in Finland. Am J Psychiatry 1994; 151: 1020-1024.
10. Calabrese JR, Shelton MD, Rapport DJ et al. Long-term treatment of bipolar disorder with lamotrigine. J Clin Psychiatry 2002; 63 (Suppl. 10): 18-22.
11. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229-233.
12. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: Results of the MAP study. Neuropsychobiol 2000; 42 (Suppl. 1): 2-10.
13. Burgess S, Geddes J, Hawton K et al. Lithium for maintenance treatment of mood disorders (Cochrane Review). Cochrane Database Syst Rev 2001; 2: CD003013.
14. Macritchie KA, Geddes JR, Scott J et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; 3: CD003196.
15. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V. A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117-120.
16. Calabrese JR, Rapport DJ, Kimmel SE et al. Controlled trials in bipolar I depression: Focus on switch rates and efficacy. Eur Neuropsychopharm 1999; 9 (Suppl. 4): 109-112.
17. Howland RH. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996; 16: 425-427.
18. Compton MT, Nemeroff CB. The treatment of bipolar depression. J Clin Psychiatry 2000; 61 (Suppl. 9): 57-67.
19. Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-550.
20. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 2002; 159: 1-50.
21. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441.
22. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled, 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
23. Calabrese J, Bowden C, Sachs G et al. A placebo-controlled, 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.
24. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841-850.
25. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.
26. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88.
27. Calabrese JR, Bowden CL, McElroy SL et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156: 1019-1023.
28. Bowden CL, Calabrese JR, McElroy SL et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patient with bipolar disorder. Biol Psychiatry 1999; 45: 953-958.
29. Bowden CL, Asnis GM, Ginsberg LD et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27: 173-184.
30. Goldsmith DR, Wagstaff AJ, Ibbotson T et al. Spotlight on lamotrigine in bipolar disorder. CNS Drugs 2004; 18: 63-67.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
32. Geddes J, Huffman R, Paska W, Evoniuk G, Leadbetter R. Lamotrigine for acute treatment of bipolar depression: Additional clinical trial data and a retrospective pooled analysis of response rates across all randomized trials conducted by GSK. Bipolar Disord 2006; 8 (Suppl. 1): 32.
33. Stolk P, Ten Berg MJ, Hemels ME et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother 2003; 37: 1891-1899.
34. Khan A, Detke M, Khan SR et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003; 191: 211-218.